A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.
paper
Cited
Public
Unavailable
- Authors
- Oslin, David W; Berrettini, Wade; Kranzler, Henry R; Pettinati, Helen; Gelernter, Joel; Volpicelli, Joseph R; O'Brien, Charles P
- Year
- 2003
- Journal
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
- PMID
- 12813472
- DOI
- 10.1038/sj.npp.1300219
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment with naltrexone.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers. | Farahbakhsh ZZ et al. | β | 2026 | β |
| A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder. | Counts C et al. | β | 2025 | β |
| Explaining increased efficacy of naltrexone in the treatment of alcohol dependent patients with a family history of alcohol use disorder: A systematic review on the role of reward sensitivity and sweet liking. | van Amsterdam J et al. | β | 2025 | β |
| Genetic liability for anxiety and treatment response to the monoamine stabilizer OSU6162 in alcohol dependence: a retrospective secondary analysis. | Hong MG et al. | β | 2025 | β |
| <i>OPRM1 rs1799971</i> Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation. | Skryabin V et al. | β | 2025 | β |
| [Naltrexone in the treatment of alcohol dependence]. | Bramness JG | β | 2025 | β |
| Precision medicine in substance use disorders: Integrating behavioral, environmental, and biological insights. | Guerrin CGJ et al. | β | 2025 | β |
| Sustained-release naltrexone for opioid dependence. | KornΓΈr H et al. | β | 2025 | β |
| Alcohol and the dopamine system. | SΓΆderpalm B et al. | β | 2024 | β |
| AUD in perspective. | de Bejczy A et al. | β | 2024 | β |
| Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance. | Beane CR et al. | β | 2024 | β |
| Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance | Beane CR et al. | β | 2023 | β |
| Male-selective effects of oxytocin agonism on alcohol intake: behavioral assessment in sociallyΒ housed prairie voles and involvement of RAGE. | Potretzke S et al. | β | 2023 | β |
| Medications for treating alcohol use disorder: A narrative review. | Kranzler HR et al. | β | 2023 | β |
| Alcohol Use Disorder: Neurobiology and Therapeutics. | Yang W et al. | β | 2022 | β |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | β | 2022 | β |
| Acute Pancreatitis: Genetic Risk and Clinical Implications. | Weiss FU et al. | β | 2021 | β |
| Association of the <i>OPRM1</i> A118G polymorphism and Pavlovian-to-instrumental transfer: Clinical relevance for alcohol dependence. | Sebold M et al. | β | 2021 | β |
| Bibliometric Insights in Genetic Factors of Substance-Related Disorders: Intellectual Developments, Turning Points, and Emerging Trends. | Wang K et al. | β | 2021 | β |
| Codeine and Tramadol Use in Athletes: A Potential for Abuse. | Zandonai T et al. | β | 2021 | β |
| Epigenetic and Genetic Factors Associated With Opioid Use Disorder: Are These Relevant to African American Populations. | Blackwood CA et al. | β | 2021 | β |
| FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. | Bach P et al. | β | 2021 | β |
| What is known about treatment aimed at indigenous people suffering from alcohol use disorder? | Andersen LAK et al. | β | 2021 | β |
| A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder. | Schick MR et al. | β | 2020 | β |
| An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence. | Lin Y et al. | β | 2020 | β |
| Differential sensitivity of alcohol drinking and partner preference to a CRFR1 antagonist in prairie voles and mice. | Potretzke S et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. | Litten RZ et al. | β | 2020 | β |
| Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. | Bach P et al. | β | 2020 | β |
| Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. | Collins D et al. | β | 2020 | β |
| Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of <i>OPRM1</i> A/G Polymorphism on Its Effectiveness. | Verholleman A et al. | β | 2020 | β |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | β | 2020 | β |
| Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. | Anton RF et al. | β | 2020 | β |
| OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. | Hendershot CS et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response. | Witkiewitz K et al. | β | 2019 | β |
| Association Study of OPRM1 Gene in a Sample of Schizophrenia Patients With Alcohol Dependence or Abuse. | Gendy MNS et al. | β | 2019 | β |
| Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. | Cannella N et al. | β | 2019 | β |
| Coevolution of Residues Provides Evidence of a Functional Heterodimer of 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R Involving Both Intracellular and Extracellular Domains. | Fongang B et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Resting state connectivity best predicts alcohol use severity in moderate to heavy alcohol users. | Fede SJ et al. | β | 2019 | β |
| Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool. | Grodin EN et al. | β | 2019 | β |
| A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. | Crist RC et al. | β | 2018 | β |
| Delta Opioid Pharmacology in Relation to Alcohol Behaviors. | Alongkronrusmee D et al. | β | 2018 | β |
| Drug-Abuse Nanotechnology: Opportunities and Challenges. | Mahmoudi M et al. | β | 2018 | β |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | β | 2018 | β |
| Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders. | Walker LC et al. | β | 2018 | β |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | β | 2018 | β |
| Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. | Anton RF et al. | β | 2018 | β |
| Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. | Soleimani Asl S et al. | β | 2018 | β |
| OPRM1 A118G and serum Ξ²-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence. | Gegenhuber B et al. | β | 2018 | β |
| [Pharmacotherapies and psychotherapies for Alcohol Dependence]. | Cottencin O | β | 2018 | β |
| The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption. | Sloan ME et al. | β | 2018 | β |
| Clinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions. | Potenza MN | β | 2017 | β |
| Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors. | Korpi ER et al. | β | 2017 | β |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | β | 2017 | β |
| Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking. | Rinker JA et al. | β | 2017 | β |
| Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. | Soyka M et al. | β | 2017 | β |
| Low ΞΌ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. | Hermann D et al. | β | 2017 | β |
| Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. | Hinton DJ et al. | β | 2017 | β |
| Pharmacotherapy of alcoholism - an update on approved and off-label medications. | Soyka M et al. | β | 2017 | β |
| Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? | Kranzler HR et al. | β | 2017 | β |
| Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. | Schacht JP et al. | β | 2017 | β |
| Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. | Rinker JA et al. | β | 2017 | β |
| Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. | Cservenka A et al. | β | 2017 | β |
| Strain-Dependent Effects of Acute Alcohol on Synaptic Vesicle Recycling and Post-Tetanic Potentiation in Medial Glutamate Inputs to the Mouse Basolateral Amygdala. | Gioia DA et al. | β | 2017 | β |
| The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? | Pomrenze MB et al. | β | 2017 | β |
| The current clinical knowledge on the treatment of gambling disorder: A summary. | Hloch K et al. | β | 2017 | β |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | β | 2017 | β |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | β | 2016 | β |
| Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. | Hendershot CS et al. | β | 2016 | β |
| Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. | Litten RZ et al. | β | 2016 | β |
| Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. | Bujarski S et al. | β | 2016 | β |
| From genetic studies to precision medicine in alcohol dependence. | Sun Y et al. | β | 2016 | β |
| Human pharmacology for addiction medicine: From evidence to clinical recommendations. | Quednow BB et al. | β | 2016 | β |
| Influence of the A118G Polymorphism of the OPRM1 Gene and Exon 3 VNTR Polymorphism of the DRD4 Gene on Cigarette Craving After Alcohol Administration. | Lechner WV et al. | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Pharmacogenomics in Psychiatric Practice. | El-Mallakh RS et al. | β | 2016 | β |
| Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment. | Williams EC et al. | β | 2016 | β |
| The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research. | Heilig M et al. | β | 2016 | β |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | β | 2016 | β |
| What the alcohol doctor ordered from the neuroscientist: Theragnostic biomarkers for personalized treatments. | Heilig M et al. | β | 2016 | β |
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. | Patriquin MA et al. | β | 2015 | β |
| Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. | Seneviratne C et al. | β | 2015 | β |
| Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. | GarcΓa ML et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Common single nucleotide variants underlying drug addiction: more than a decade of research. | BΓΌhler KM et al. | β | 2015 | β |
| Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. | Fredriksson I et al. | β | 2015 | β |
| Gambling disorder and other behavioral addictions: recognition and treatment. | Yau YH et al. | β | 2015 | β |
| Gene-gene interaction of ΞΌ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. | Misailidis G et al. | β | 2015 | β |
| Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. | Litten RZ et al. | β | 2015 | β |
| Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study. | Pal R et al. | β | 2015 | β |
| KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction. | Padula AE et al. | β | 2015 | β |
| OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. | Foulds JA et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| Pharmacotherapy for alcohol dependence: A stratified approach. | Thompson A et al. | β | 2015 | β |
| Pharmacotherapy for alcohol use disorder: current and emerging therapies. | Swift RM et al. | β | 2015 | β |
| Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study. | Worley MJ et al. | β | 2015 | β |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | β | 2015 | β |
| The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. | Ripley TL et al. | β | 2015 | β |
| The opioid receptors as targets for drug abuse medication. | Noble F et al. | β | 2015 | β |
| The pharmacogenetics of alcohol use disorder. | Jones JD et al. | β | 2015 | β |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | β | 2015 | β |
| Addiction science: Uncovering neurobiological complexity. | Volkow ND et al. | β | 2014 | β |
| Alcohol-medical drug interactions. | Johnson BA et al. | β | 2014 | β |
| A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. | Wong CJ et al. | β | 2014 | β |
| A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. | Pettinati HM et al. | β | 2014 | β |
| Association between alcohol-cue modulated startle reactions and drinking behaviour in alcohol dependent patients - results of the PREDICT study. | LemΓ©nager T et al. | β | 2014 | β |
| Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPΞ³S binding in mice with Oprm1 A112G. | Wang YJ et al. | β | 2014 | β |
| Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. | Garbutt JC et al. | β | 2014 | β |
| Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. | Henderson-Redmond A et al. | β | 2014 | β |
| Future pharmacological treatments for substance use disorders. | Forray A et al. | β | 2014 | β |
| Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. | Enoch MA | β | 2014 | β |
| Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. | Jonas DE et al. | β | 2014 | β |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. | Ray LA et al. | β | 2014 | β |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | β | 2014 | β |
| Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. | Hendershot CS | β | 2014 | β |
| Pharmacogenetics of addiction therapy. | Nielsen DA et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. | Caputo F et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| Pharmacotherapy of alcohol use disorders: seventy-five years of progress. | Zindel LR et al. | β | 2014 | β |
| Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. | Mann K et al. | β | 2014 | β |
| Progress in addiction treatment: from one-size-fits-all to medications and treatment matching. | Woody GE | β | 2014 | β |
| The behavioral economics of substance use disorders: reinforcement pathologies and their repair. | Bickel WK et al. | β | 2014 | β |
| The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. | Grant JE et al. | β | 2014 | β |
| Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine? | Leggio L et al. | β | 2014 | β |
| Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. | Batki SL et al. | β | 2014 | β |
| A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. | Strobel B et al. | β | 2013 | β |
| Alcohol addiction: toward a patient-oriented pharmacological treatment. | Addolorato G et al. | β | 2013 | β |
| Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: results from a large multicenter association study. | Preuss UW et al. | β | 2013 | β |
| Association of VMAT2 gene polymorphisms with alcohol dependence. | Fehr C et al. | β | 2013 | β |
| A systems medicine research approach for studying alcohol addiction. | Spanagel R et al. | β | 2013 | β |
| Current status of co-occurring mood and substance use disorders: a new therapeutic target. | Pettinati HM et al. | β | 2013 | β |
| DSM-5 criteria for substance use disorders: recommendations and rationale. | Hasin DS et al. | β | 2013 | β |
| Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice. | Tomie A et al. | β | 2013 | β |
| Improving clinical outcomes for naltrexone as a management of problem alcohol use. | Hulse GK | β | 2013 | β |
| Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. | Schacht JP et al. | β | 2013 | β |
| Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients. | Marini V et al. | β | 2013 | β |
| Is the rodent maternal separation model a valid and effective model for studies on the early-life impact on ethanol consumption? | Nylander I et al. | β | 2013 | β |
| Management of alcohol dependence in patients with liver disease. | Addolorato G et al. | β | 2013 | β |
| Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. | Ducat E et al. | β | 2013 | β |
| Neurochemical heterogeneity of rats predicted by different measures to be high ethanol consumers. | Barson JR et al. | β | 2013 | β |
| Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. | McLemore GL et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. | Manini AF et al. | β | 2013 | β |
| Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. | Jacob C | β | 2013 | β |
| Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. | Hajj A et al. | β | 2013 | β |
| Pharmacotherapy for alcohol dependence: status of current treatments. | Franck J et al. | β | 2013 | β |
| Role of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of marchigian sardinian alcohol-preferring rats. | Ayanwuyi LO et al. | β | 2013 | β |
| Subjective response to alcohol among alcohol-dependent individuals: effects of the ΞΌ-opioid receptor (OPRM1) gene and alcoholism severity. | Ray LA et al. | β | 2013 | β |
| Targeted opioid receptor antagonists in the treatment of alcohol use disorders. | Niciu MJ et al. | β | 2013 | β |
| The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. | Bazov I et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| Update on the Pharmacological Treatment of Pathological Gambling. | Bullock SA et al. | β | 2013 | β |
| Variation in Mu-Opioid Receptor Gene <i>(OPRM1)</i> as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. | Chen AC et al. | β | 2013 | β |
| Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. | Kranzler HR et al. | β | 2013 | β |
| Ξ²-Arrestin 2 knockout mice exhibit sensitized dopamine release and increased reward in response to a low dose of alcohol. | BjΓΆrk K et al. | β | 2013 | β |
| Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. | Witkiewitz K et al. | β | 2012 | β |
| A common single nucleotide polymorphism A118G of theΒ ΞΌ opioid receptor alters its N-glycosylation and protein stability. | Huang P et al. | β | 2012 | β |
| Ambulatory monitoring in the genetics of psychosomatic medicine. | Finan PH et al. | β | 2012 | β |
| Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. | Proudnikov D et al. | β | 2012 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. | Lingford-Hughes AR et al. | β | 2012 | β |
| [Clinical alcohology]. | Cottencin O et al. | β | 2012 | β |
| Common and specific liability to addiction: approaches to association studies of opioid addiction. | Nielsen DA et al. | β | 2012 | β |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. | Ashenhurst JR et al. | β | 2012 | β |
| Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence. | Langleben DD et al. | β | 2012 | β |
| Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. | van Rijn RM et al. | β | 2012 | β |
| Genetic and environmental determinants of stress responding. | Clarke TK et al. | β | 2012 | β |
| Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. | Zhang H et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Medications development to treat alcohol dependence: a vision for the next decade. | Litten RZ et al. | β | 2012 | β |
| Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. | Al-Eitan LN et al. | β | 2012 | β |
| Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. | Anton RF et al. | β | 2012 | β |
| Neuropeptides as mediators of the early-life impact on the brain; implications for alcohol use disorders. | Nylander I et al. | β | 2012 | β |
| Pathological Gambling: Neuropsychopharmacology and Treatment. | Bullock SA et al. | β | 2012 | β |
| Personalized treatment of alcohol dependence. | Kranzler HR et al. | β | 2012 | β |
| Pharmacogenetically driven treatments for alcoholism: are we there yet? | Arias AJ et al. | β | 2012 | β |
| Pharmacogenetics of alcoholism: a clinical neuroscience perspective. | Ray LA et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms. | Koller G et al. | β | 2012 | β |
| Reduced expression of the ΞΌ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. | Wang YJ et al. | β | 2012 | β |
| The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction. | Burkett JP et al. | β | 2012 | β |
| The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. | Srinivasan S et al. | β | 2012 | β |
| The genetic basis of addictive disorders. | Ducci F et al. | β | 2012 | β |
| The genetics of addiction-a translational perspective. | Agrawal A et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. | Bujarski S et al. | β | 2012 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| Alcohol research: past, present, and future. | Gunzerath L et al. | β | 2011 | β |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | β | 2011 | β |
| Genetics of alcohol dependence. | Kimura M et al. | β | 2011 | β |
| Medications for unhealthy alcohol use: across the spectrum. | O'Malley SS et al. | β | 2011 | β |
| Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. | Lobmaier PP et al. | β | 2011 | β |
| Neuroscience of behavioral and pharmacological treatments for addictions. | Potenza MN et al. | β | 2011 | β |
| OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. | Coller JK et al. | β | 2011 | β |
| OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques. | Schwandt ML et al. | β | 2011 | β |
| Personalized addiction treatment: how close are we? | Oslin D | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. | Sadee W et al. | β | 2011 | β |
| Predictors for the efficacy of naltrexone treatment in alcohol dependence: sweet preference. | Laaksonen E et al. | β | 2011 | β |
| Relapse prevention for addictive behaviors. | Hendershot CS et al. | β | 2011 | β |
| Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. | Yoon G et al. | β | 2011 | β |
| Social hedonic capacity is associated with the A118G polymorphism of the mu-opioid receptor gene (OPRM1) in adult healthy volunteers and psychiatric patients. | Troisi A et al. | β | 2011 | β |
| Stress-induced and cue-induced craving for alcohol in heavy drinkers: Preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. | Ray LA | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| The response to naltrexone in ethanol-drinking rats depends on early environmental experiences. | Daoura L et al. | β | 2011 | β |
| Why health care process performance measures can have different relationships to outcomes for patients and hospitals: understanding the ecological fallacy. | Finney JW et al. | β | 2011 | β |
| A cognitive model for the intergenerational transference of alcohol use behavior. | Campbell JM et al. | β | 2010 | β |
| Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs. | Kalman D et al. | β | 2010 | β |
| Alcohol biomarkers in applied settings: recent advances and future research opportunities. | Litten RZ et al. | β | 2010 | β |
| Alcohol response and consumption in adolescent rhesus macaques: life history and genetic influences. | Schwandt ML et al. | β | 2010 | β |
| A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. | Vallender EJ et al. | β | 2010 | β |
| Breaking barriers in the genomics and pharmacogenetics of drug addiction. | Ho MK et al. | β | 2010 | β |
| ChIP-chip analysis of neurexins and other candidate genes for addiction and neuropsychiatric disorders. | Pedrosa E et al. | β | 2010 | β |
| Chronic ethanol exposure produces tolerance to elevations in neuroactive steroids: mechanisms and reversal by exogenous ACTH. | Boyd KN et al. | β | 2010 | β |
| Commentary on Nelson et al. (2010). | Barr CS | β | 2010 | β |
| Consilient research approaches in studying gene x environment interactions in alcohol research. | Sher KJ et al. | β | 2010 | β |
| Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. | Zhou Y et al. | β | 2010 | β |
| Emerging drugs to treat alcoholism. | Soyka M et al. | β | 2010 | β |
| Heroin-assisted treatment in the Netherlands: History, findings, and international context. | Blanken P et al. | β | 2010 | β |
| Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society. | Comer SD et al. | β | 2010 | β |
| Individualised treatment in alcohol-dependent patients. | Mann K et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| Medication treatment of different types of alcoholism. | Johnson BA | β | 2010 | β |
| Nalmefene for treatment of alcohol dependence. | Soyka M et al. | β | 2010 | β |
| Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. | Ray LA et al. | β | 2010 | β |
| Neural markers of genetic vulnerability to drug addiction. | MΓΌller DJ et al. | β | 2010 | β |
| [Neurobiology and genetics of addiction]. | Kiefer F | β | 2010 | β |
| Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. | Chatterjee S et al. | β | 2010 | β |
| Neuropharmacology of addiction and how it informs treatment. | Lingford-Hughes A et al. | β | 2010 | β |
| NIAAA: advancing alcohol research for 40 years. | Warren KR et al. | β | 2010 | β |
| Opioid antagonists for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of alcohol and alcohol dependence treatment. | Kranzler HR et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. | Ray LA et al. | β | 2010 | β |
| Preclinical evidence of new opioid modulators for the treatment of addiction. | RodrΓguez-Arias M et al. | β | 2010 | β |
| Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. | Ray LA et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| Substance abuse is a disease of the human brain: focus on alcohol. | Anton R | β | 2010 | β |
| Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. | Hutchison KE | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. | Ray LA et al. | β | 2010 | β |
| The opioid systems--panacea and nemesis. | Terenius L et al. | β | 2010 | β |
| The pharmacotherapy of alcohol dependence: a state of the art review. | De Sousa A | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| What aspects of human alcohol use disorders can be modeled using selectively bred rat lines? | Froehlich JC | β | 2010 | β |
| Alcoholism: a systems approach from molecular physiology to addictive behavior. | Spanagel R | β | 2009 | β |
| A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. | Kim SG et al. | β | 2009 | β |
| A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. | Ray LA et al. | β | 2009 | β |
| Bidirectional translational research: Progress in understanding addictive diseases. | Kreek MJ et al. | β | 2009 | β |
| Clinical Case Discussion: Pathological Gambling and Nicotine Dependence. | Grant JE et al. | β | 2009 | β |
| Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking. | Oslin DW et al. | β | 2009 | β |
| Effects of alcoholism typology on response to naltrexone in the COMBINE study. | Bogenschutz MP et al. | β | 2009 | β |
| Ethical considerations for administering alcohol or alcohol cues to treatment-seeking alcoholics in a research setting: can the benefits to society outweigh the risks to the individual? A commentary in the context of the National Advisory Council on Alcohol Abuse and Alcoholism -- Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation (2005). | Enoch MA et al. | β | 2009 | β |
| Genetics of alcohol dependence. | Gelernter J et al. | β | 2009 | β |
| Identifying the neural circuitry of alcohol craving and relapse vulnerability. | Heinz A et al. | β | 2009 | β |
| Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. | Ray LA et al. | β | 2009 | β |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | β | 2009 | β |
| Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. | Boettiger CA et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Pathological Gambling: Biological and Clinical Considerations. | Topf JL et al. | β | 2009 | β |
| Penn/VA center for studies of addiction. | O'Brien CP et al. | β | 2009 | β |
| Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. | Ooteman W et al. | β | 2009 | β |
| Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. | Wiers RW et al. | β | 2009 | β |
| Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. | Pratt WM et al. | β | 2009 | β |
| Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. | Mann K et al. | β | 2009 | β |
| Stress, alcohol and drug interaction: an update of human research. | Uhart M et al. | β | 2009 | β |
| Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. | Garbutt JC et al. | β | 2009 | β |
| An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. | Anton RF et al. | β | 2008 | β |
| A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. | Gironi M et al. | β | 2008 | β |
| A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. | Oslin DW et al. | β | 2008 | β |
| Approach to the genetics of alcoholism: a review based on pathophysiology. | KΓΆhnke MD | β | 2008 | β |
| Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. | Ehlers CL et al. | β | 2008 | β |
| Cloninger's typology and treatment outcome in alcohol-dependent subjects during pharmacotherapy with naltrexone. | Kiefer F et al. | β | 2008 | β |
| Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. | Heitjan DF et al. | β | 2008 | β |
| Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. | Filbey FM et al. | β | 2008 | β |
| Disposition of naltrexone after intravenous bolus administration in Wistar rats, low-alcohol-drinking rats and high-alcohol-drinking rats. | Akala EO et al. | β | 2008 | β |
| Drugs for relapse prevention of alcoholism: ten years of progress. | Spanagel R et al. | β | 2008 | β |
| Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. | Arias AJ et al. | β | 2008 | β |
| Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. | Filbey FM et al. | β | 2008 | β |
| Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. | Suh JJ et al. | β | 2008 | β |
| Genetic approaches to addiction: genes and alcohol. | Ducci F et al. | β | 2008 | β |
| Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. | Anton RF | β | 2008 | β |
| Matching clients to psychosocial treatments: at the cusp of hope and evidence? | Finney JW | β | 2008 | β |
| Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. | Tidey JW et al. | β | 2008 | β |
| Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. | O'Malley SS et al. | β | 2008 | β |
| Naltrexone in the treatment of alcohol dependence. | Unterwald EM | β | 2008 | β |
| Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. | Nikoshkov A et al. | β | 2008 | β |
| Practitioner review: adolescent alcohol use disorders: assessment and treatment issues. | Perepletchikova F et al. | β | 2008 | β |
| Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. | Grant JE et al. | β | 2008 | β |
| Proton magnetic resonance spectroscopy in alcohol use disorders: a potential new endophenotype? | Meyerhoff DJ et al. | β | 2008 | β |
| Review. Evidence-based treatments of addiction. | O'Brien CP | β | 2008 | β |
| Review. Genetics of addictions: strategies for addressing heterogeneity and polygenicity of substance use disorders. | Wong CC et al. | β | 2008 | β |
| Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. | Potenza MN | β | 2008 | β |
| Role of a functional human gene polymorphism in stress responsivity and addictions. | Kreek MJ | β | 2008 | β |
| Role of pharmacogenetics in variable response to drugs: focus on opioids. | Kadiev E et al. | β | 2008 | β |
| Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. | Krishnan-Sarin S et al. | β | 2008 | β |
| Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. | Johnson BA | β | 2008 | β |
| Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. | Barr CS et al. | β | 2008 | β |
| Acamprosate in alcohol dependence: implications of a unique mechanism of action. | Littleton JM | β | 2007 | β |
| A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. | van den Wildenberg E et al. | β | 2007 | β |
| Alcohol use and anxiety: diagnostic and management issues. | Brady KT et al. | β | 2007 | β |
| Associations of the dopamine D4 receptor gene VNTR polymorphism with drug use in adolescent psychiatric inpatients. | McGeary JE et al. | β | 2007 | β |
| Downregulation of mu opioid receptor by RNA interference in the ventral tegmental area reduces ethanol consumption in mice. | Lasek AW et al. | β | 2007 | β |
| Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls. | Mitchell JM et al. | β | 2007 | β |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. | Glatt SJ et al. | β | 2007 | β |
| Evolving '-omics' technologies in the drug development process. | Kraljevic Pavelic S et al. | β | 2007 | β |
| Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. | Krishnan-Sarin S et al. | β | 2007 | β |
| Gene-environment interactions in addictive disorders: epidemiological and methodological aspects. | Gorwood P et al. | β | 2007 | β |
| Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. | Hansson AC et al. | β | 2007 | β |
| Gene transcription alterations associated with decrease of ethanol intake induced by naltrexone in the brain of Wistar rats. | Oliva JM et al. | β | 2007 | β |
| Imagen: implications for addiction science and science policy. | Heilig M | β | 2007 | β |
| Long-acting injectable naltrexone for the treatment of alcohol dependence. | Mannelli P et al. | β | 2007 | β |
| Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. | Job MO et al. | β | 2007 | β |
| Naltrexone long-acting formulation in the treatment of alcohol dependence. | Johnson BA | β | 2007 | β |
| Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment. | Davidson D et al. | β | 2007 | β |
| New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. | Gueorguieva R et al. | β | 2007 | β |
| Opioid dependence and addiction during opioid treatment of chronic pain. | Ballantyne JC et al. | β | 2007 | β |
| Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. | Gelernter J et al. | β | 2007 | β |
| Pharmacogenetics of opioids. | Somogyi AA et al. | β | 2007 | β |
| Pharmacogenetics of the Β΅-opioid receptor and the treatment of addictions. | Ray LA et al. | β | 2007 | β |
| Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. | van der Zwaluw CS et al. | β | 2007 | β |
| The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. | Mitchell JM et al. | β | 2007 | β |
| The biological bases of nicotine and alcohol co-addiction. | Li TK et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. | Kroslak T et al. | β | 2007 | β |
| Toward a rational selection of treatment for addiction. | O'Brien CP | β | 2007 | β |
| Treatment of addiction in the era of genomic medicine. | O'Brien C | β | 2007 | β |
| Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. | Kellogg S et al. | β | 2006 | β |
| Alcoholism clinical trials. | O'Brien C | β | 2006 | β |
| Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. | Bart G et al. | β | 2006 | β |
| An overview of the genetics of substance use disorders. | Lachman HM | β | 2006 | β |
| A rational approach to the pharmacotherapy of alcohol dependence. | Petrakis IL | β | 2006 | β |
| Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. | Arias A et al. | β | 2006 | β |
| Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. | Ray R et al. | β | 2006 | β |
| A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence. | Johnson BA | β | 2006 | β |
| A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. | Roozen HG et al. | β | 2006 | β |
| Choosing the right medication for the treatment of alcoholism. | Pettinati HM et al. | β | 2006 | β |
| Different lengths of times for progressions in adolescent substance involvement. | Ridenour TA et al. | β | 2006 | β |
| Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. | Balboni G et al. | β | 2006 | β |
| Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. | Ciccocioppo R et al. | β | 2006 | β |
| Genetic moderators of naltrexone's effects on alcohol cue reactivity. | McGeary JE et al. | β | 2006 | β |
| Genetics and alcoholism: how close are we to potential clinical applications? | Quickfall J et al. | β | 2006 | β |
| Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment. | Overstreet DH et al. | β | 2006 | β |
| Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. | Drakenberg K et al. | β | 2006 | β |
| New findings on the genetic influences on alcohol use and dependence. | Higuchi S et al. | β | 2006 | β |
| Non-human primate models of inheritance vulnerability to alcohol use disorders. | Barr CS et al. | β | 2006 | β |
| Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. | Jung YC et al. | β | 2006 | β |
| Should addictive disorders include non-substance-related conditions? | Potenza MN | β | 2006 | β |
| Symbiotic relationship of pharmacogenetics and drugs of abuse. | Rutter JL | β | 2006 | β |
| Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. | Oslin DW et al. | β | 2006 | β |
| The effect of olanzapine on craving and alcohol consumption. | Hutchison KE et al. | β | 2006 | β |
| The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. | Chong RY et al. | β | 2006 | β |
| The neurobiology of substance and behavioral addictions. | Grant JE et al. | β | 2006 | β |
| The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. | Pettinati HM et al. | β | 2006 | β |
| Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. | Hansson AC et al. | β | 2006 | β |
| Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. | Zhang Y et al. | β | 2005 | β |
| Anticraving medications for relapse prevention: a possible new class of psychoactive medications. | O'Brien CP | β | 2005 | β |
| Are mu-opioid receptor polymorphisms important for clinical opioid therapy? | LΓΆtsch J et al. | β | 2005 | β |
| Challenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industry. | Johnson BA et al. | β | 2005 | β |
| Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? | Rubio G et al. | β | 2005 | β |
| Clock reset for alcoholism. | Yuferov V et al. | β | 2005 | β |
| Development of medications for alcohol use disorders: recent advances and ongoing challenges. | Litten RZ et al. | β | 2005 | β |
| [DNA polymorphisms and alcoholism]. | Pastor I et al. | β | 2005 | β |
| Genomic medicine: genetic variation and its impact on the future of health care. | Willard HF et al. | β | 2005 | β |
| Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. | Bart G et al. | β | 2005 | β |
| Is there a case for extended interventions for alcohol and drug use disorders? | McKay JR | β | 2005 | β |
| Microarray studies of psychostimulant-induced changes in gene expression. | Yuferov V et al. | β | 2005 | β |
| Naloxone does not attenuate the locomotor effects of ethanol in FAST, SLOW, or two heterogeneous stocks of mice. | Holstein SE et al. | β | 2005 | β |
| Neurobiology of addiction: treatment and public policy ramifications. | Dackis C et al. | β | 2005 | β |
| Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. | Smith RJ et al. | β | 2005 | β |
| Opioid antagonists for alcohol dependence. | Srisurapanont M et al. | β | 2005 | β |
| Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. | Kreek MJ et al. | β | 2005 | β |
| Pharmacotherapy and other treatments for cocaine abuse and dependence. | Vocci FJ et al. | β | 2005 | β |
| Pharmacotherapy and pharmacogenetics of nicotine dependence. | Berrettini WH et al. | β | 2005 | β |
| Pharmacotherapy for alcohol dependence. | Wortman SM et al. | β | 2005 | β |
| Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. | Verheul R et al. | β | 2005 | β |
| The contribution of genetics to addiction therapy approaches. | Edenberg HJ et al. | β | 2005 | β |
| Treating tobacco dependence: state of the science and new directions. | Lerman C et al. | β | 2005 | β |
| Treatment of late-life depression complicated by alcohol dependence. | Oslin DW | β | 2005 | β |
| Alcoholism: genes and mechanisms. | Oroszi G et al. | β | 2004 | β |
| A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. | Ray LA et al. | β | 2004 | β |
| Association of functional opioid receptor genotypes with alcohol dependence in Koreans. | Kim SG et al. | β | 2004 | β |
| Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. | Kreek MJ et al. | β | 2004 | β |
| Genes associated with addiction: alcoholism, opiate, and cocaine addiction. | Kreek MJ et al. | β | 2004 | β |
| Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. | Anton RF et al. | β | 2004 | β |
| Opioids and alcoholism. | Oswald LM et al. | β | 2004 | β |
| Recent advances in the pharmacotherapy of alcoholism. | Myrick H et al. | β | 2004 | β |
| Setting priorities for genomic research. | Berrettini W et al. | β | 2004 | β |
| Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. | Bart G et al. | β | 2004 | β |
| The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. | Lerman C et al. | β | 2004 | β |
| Positron emission tomography--a tool for identifying the effects of alcohol dependence on the brain. | Wong DF et al. | β | 2003 | β |